Principaux documents

Voir toute la documentation

P5515

Prostaglandin E₁

Name: Prostaglandin E<SUB>1</SUB>
Brand: SIGMA

≥98% (HPLC), powder, vasodilator

Synonyme(s) :

(11α,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid, Alprostadil, PGE₁

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :

C₂₀H₃₄O₅

Numéro CAS:

745-65-3

Poids moléculaire :

354.48

PubChem Substance ID:

57654538

eCl@ss:

42020658

UNSPSC Code:

12352211

NACRES:

NA.77

EC Number:

212-017-2

MDL number:

MFCD00077860

Beilstein/REAXYS Number:

5294062

Assay:

≥98% (HPLC)

Form:

(powder to crystals)

Quality level:

200

Service technique

Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.

Laissez-nous vous aider

Propriétés

Nom du produit

Prostaglandin E₁, ≥98% (HPLC), synthetic

biological source

synthetic

Quality Level

200

assay

≥98% (HPLC)

form

(powder to crystals)

solubility

ethanol: 5 mg/mL

storage temp.

−20°C

SMILES string

O=C1[C@H](CCCCCCC(O)=O)[C@@H](/C=C/[C@H](CCCCC)O)[C@H](O)C1

InChI

1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1

InChI key

GMVPRGQOIOIIMI-DWKJAMRDSA-N

Gene Information

human ... PTGER1(5731), PTGER2(5732), PTGIR(5739)
mouse ... Ptger1(19216), Ptger2(19217), Ptger3(19218), Ptger4(19219)

Description

Application

Prostaglandin E1 has been used:

as a platelet inhibitor to analyse its effect on autophagy
in platelet adhesion assay
to investigate its effect on cAMP production in thyroid glands of normal and growth-retarded mouse in vitro.

Biochem/physiol Actions

Prostaglandin E1 (PGE1) is a hormone synthesized from dihomo-γ-linolenic acid (DGLA) by the action of enzyme prostaglandin synthase. It is a vasodilator and activates adenylate cyclase. It is majorly present in human semen and is a potent platelet aggregation inhibitor. PGE1 infusions is effective in treating limb ischemia and peripheral vascular disease. It is unstable and is hydrolyzed to PGA1 in the lungs. Nanoparticle encapsulation of PGE1 is essential for its delivery at the vascular injury site. It elicits vasodilator effects on the retinal artery and vein in central retinal artery occlusion (CRAO). PGE1 and its synthetic analog misoprostol interact with E-prostanoid receptor 4 (EP4) and elicits protection in chronic myelogenous leukemia (CML).

Still not finding the right product?

Explore all of our products under

pictograms

GHS06

signalword

Danger

hcodes

H301

pcodes

P301 + P310 + P330

Hazard Classifications

Acute Tox. 3 Oral

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Articles

Discover Bioactive Small Molecules for Lipid Signaling Research

Contenu apparenté

An Update on Ligands for Prostanoid Receptors

Product Information Sheet - P5515

In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step.

Mélanie Abonnenc et al.

Blood transfusion = Trasfusione del sangue, 13(2), 255-264 (2014-11-05)

The Intercept Blood SystemTM (Cerus) is used to inactivate pathogens in platelet concentrates (PC). The aim of this study was to elucidate the extent to which the Intercept treatment modifies the functional properties of platelets. A two-arm study was conducted

Intravenous infusion of prostaglandin E1 therapy in extremity ischemia

Ramakrishna P

Indian Journal of Vascular and Endovascular Surgery, 4(2), 38-38 (2017)

Synthesis of prostaglandin E 1 phosphate derivatives and their encapsulation in biodegradable nanoparticles

Takeda M, et al.

Pharmaceutical Research, 26(7), 1792-1800 (2009)

Afficher tous les articles scientifiques apparentés

Numéro d'article de commerce international

Référence	GTIN
P5515-1MG	04061834391845
P5515-5MG	04061834391852
P5515-10MG	04061834391838